Cardiovascular & Soft Tissue Repair Patch Market (Product: Synthetic Patch and Biologic Patch [Xenogeneic Patch and Allogeneic Patch]; Application: Cardiovascular Repair [Cardiac Reconstruction and Vascular Reconstruction] and Soft Tissue Repair [Abdominal Wall Reconstruction, Thoracic Wall Reconstruction, Dural Reconstruction, Hernia Repair, and Others]; and End User: Hospitals, Ambulatory Surgical Centers, and Specialty Clinics) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2030

Description

Progress in Tissue Engineering to Drive Global Market

The past couple of decades have witnessed significant progress in technology that has played a key role in improving the different cardiac treatments and patient outcomes. Advancements in biomedicine have led to an increase in the deployment of natural bio polyesters such as polyhydroxyalkanoates (PHA) for an array of applications. As PHAs are biodegradable, biocompatible, and non-toxic, they are used in multiple applications as biomaterials. PHAs are also used in the implantology space as valves and sutures in the tissue engineering field as substitutes for a bone graft and cardiovascular patches. The significant rise in the number of congenital & acquired cardiovascular and soft tissue anomalies, rising demand for biologics for hernia and other soft tissue repair, and rapid progress in biomaterial and tissue engineering are some of the major factors that are expected to drive the cardiovascular & soft tissue repair patch market during the forecast period (2019-2027).

Research and development activities in the cardiovascular & soft tissue repair patch market are on the rise as healthcare providers continue to find new materials that will improve the effectiveness of these patches. Growing adoption of cardiovascular & soft tissue repair patches particularly for cardiac tissue engineering is expected to be a major driver that is projected to steer the global cardiovascular & soft tissue repair patch market past the ~US$ 4.4 Bn mark by the end of 2027.

Improvements in Bio-based Techniques to Treat Cardiac Regeneration Likely to Fuel Demand

Cardiovascular diseases are the leading causes of death worldwide and the numbers surge each year. Of all major cardiovascular diseases, the prevalence of myocardial infarction (MI) is the highest. Another major cardiovascular condition that is likely to be a burden on the global healthcare systems is heart failure wherein the heart loses its functional capabilities. While there is no concrete treatment for heart failure, research and development activities continue to open up new opportunities in this field.

Get a glimpse of the in-depth analysis through our Report Brochure

In the past couple of decades, tissue regeneration to enhance cardiac degeneration and mitigate heart failure has emerged as an ideal solution wherein cardiovascular & soft tissue repair patches made of biomaterials are used. Apart from tissue engineering, noteworthy advancements in regenerative medicine have also opened up new opportunities for stakeholders in the cardiovascular & soft tissue repair patch market. Over the past few years, participants of the cardiovascular & soft tissue repair patch market are focusing on the development of biomaterial-based strategies to overcome cardiac regeneration post-myocardial infarction. In the current scenario, the two major techniques deployed for tissue engineering include cardiac patches and in situ gelling systems. Cardiovascular & soft tissue repair patches consist of cells and bioactive molecules that aid in the therapeutic healing and repair of soft tissues. Despite emerging as one of the most reliable and effective tissue engineering techniques, cardiovascular & soft tissue repair patches have received flak, as they require invasive surgeries for implantation. In the past few years, in situ gel systems gaining popularity. However, it could dent the prospects of cardiovascular & soft tissue repair patches in the near future.

R&D Paves Way for New Cardiovascular & Soft Tissue Repair Patches

Research and development activities have been critical in the field of biomedicine and biomedical engineering. Witnessing the growing demand for efficient solutions to repair or heal the structural changes of the heart post-myocardial infarction treatment has encouraged research and development in the current cardiovascular & soft tissue repair patch market. While stem cell therapies have offered significant promise in providing assistance for cardiac repair, the low retention capacity of the transplanted stem cells poses a major hurdle. Various drawbacks of alternative techniques to aid cardiac repair have encouraged researchers to focus on the discovery of new solutions.

For instance, a group of researchers from the U.S. and South Korea designed a new stretchable cardiovascular & soft tissue repair patch made using a cell-derived extracellular matrix (ECM). According to the researchers, ECM can play an important role in enhancing the adhesion of stem cells and accelerate the recovery process. Investments in research and development activities are expected to grow at a steady pace in the coming years due to which, new therapeutic cardiovascular & soft tissue repair patches are being developed using new biomaterials.

Analysts’ Viewpoint

The global cardiovascular & soft tissue repair patch market is expected to grow at an impressive CAGR of ~10% during the forecast period. The market growth can be attributed to a range of factors, including rise in the prevalence of congenital & acquired cardiovascular and soft tissue anomalies and ascending demand for biologics for hernia and a range of other soft tissue repair applications. Stakeholders in the current cardiovascular & soft tissue repair patch market should focus on research and development activities to develop new and effective therapeutic cardiac patches. In addition, developments in the biomaterial and tissue engineering space are further expected to boost the prospects of the market for cardiovascular & soft tissue repair patches.

Cardiovascular & Soft Tissue Repair Patch Market: Overview

The global cardiovascular & soft tissue repair patch market for the historical period (2017–2018) and forecast period (2019–2027), increase in geriatric population and rise in prevalence of congenital & acquired cardiovascular and soft tissue anomalies are projected to boost the growth of the global cardiovascular & soft tissue repair patch market during the forecast period. Moreover, inclination toward minimally invasive procedures is anticipated to fuel the growth of the global cardiovascular & soft tissue repair patch market.

According to the report, the global cardiovascular & soft tissue repair patch market was valued at US$ 1.9 Bn in 2018 and is expected to expand at a CAGR of ~10% from 2019 to 2027

Rise in Prevalence of Congenital & Acquired Cardiovascular and Soft Tissue Anomalies: Key Drivers

The number of people with congenital heart defects is increasing across the globe due to changes in lifestyle, dietary habits, and physical inactivity. Rise in prevalence of congenital heart defects such as atrial septal defects and ventricular septal defects is likely to fuel the growth of the global cardiovascular & soft tissue repair patch market.

According to the Centers for Disease Control and Prevention, an estimated 1% (40,000) babies are born with congenital heart defect in the U.S. every year, and ventricular septal defect (VSD) is the most common heart defect

Rise in demand for biologics, owing to increase in soft tissue repair procedures is likely to propel the cardiovascular & soft tissue repair patch market. According to the U.S. Food and Drug Administration, over 1 million hernia repairs are performed in the U.S. each year.

Increase in incidence of abdominal and other types of hernia, surge in usage of biologic patches i.e., xenogeneic patch & allogeneic patch, and inclination toward minimally invasive procedures leading to rise in demand for biologic cardiovascular & soft tissue repair patch products

Increase in Geriatric Population

The geriatric population is at high risk of developing heart-related problems. Aging leads to accentuated adverse remodeling and increased dysfunction of cardiac mechanism. As the population continues to age, older patients are being referred for repair of acquired VSD. Hence, increase in the geriatric population is projected to accelerate the growth of the cardiovascular & soft tissue repair patch market during the forecast period.

According to the U.S. Department of Health & Human Product estimates, the U.S. will have about 72.1 million elderly people by 2030, which is more than twice the number in 2000

According to World Population Prospects: the 2019 Revision, the population aged 65 and above is increasing faster than all other age groups across the globe

Availability of Alternate Treatments and Complications Associated with Patches Restrain Global Market

Cardiovascular & soft tissue repair are common procedures performed across the world. Herniorrhaphy and hernioplasty are the alternative treatments for hernia repair.

Mesh for hernia repair and valve for cardiovascular repair are used significantly across the globe. Hence, alternative treatments are likely to hamper the growth of the cardiovascular & soft tissue repair market.

Adhesion, seroma, recurrence of soft tissue defects or hernia, allergic reactions, and hematomas are the complications associated with patches which restrict their usage. This factor hampers the growth of the global cardiovascular & soft tissue repair patch market.

Cardiovascular & Soft Tissue Repair Patch Market: Competition Landscape

This report profiles major players in the global cardiovascular & soft tissue repair patch market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments

The global cardiovascular & soft tissue repair patch market is moderately fragmented, with presence of a small number of large players in international markets and large number of small players in regional markets. Top 4 to 5 players hold majority share of the global cardiovascular & soft tissue repair patch market. Prominent players operating in the global cardiovascular & soft tissue repair patch market include

  • W. L. Gore & Associates, Inc.
  • BD, Edwards Lifesciences Corporation
  • CryoLife, Inc.
  • Baxter
  • Johnson & Johnson (Medical Devices Business Services, Inc.)
  • Aesculap, Inc. (B. Braun company)
  • Nurami Medical Nanofiber Technology
  • Medtronic
  • FOC Medical S.A.
  • Medprin Regenerative Medical Technologies Co., Ltd.
  • CorMatrix, Inc.
  • Terumo Corporation
  • Lamed GmbH
  •  South America Implants S.A.

Key Questions Answered in Cardiovascular & Soft Tissue Repair Patch Market Report

  • What is the scope of growth of product companies in the global cardiovascular & soft tissue repair patch market?
  • What will be the Y-o-Y growth of the global cardiovascular & soft tissue repair patch market between 2019 and 2027?
  • What is the influence of changing trends in technologies on the global cardiovascular & soft tissue repair patch market?
  • Will North America continue to be the most profitable regional market for cardiovascular & soft tissue repair patch providers?
  • Which factors will hamper the growth of the global cardiovascular & soft tissue repair patch market during the forecast period?
  • Which are the leading companies in the global cardiovascular & soft tissue repair patch market?

Cardiovascular & Soft Tissue Repair Patch Market - Segmentation

Product

  • Synthetic Patch
  • Biologic Patch
  • Xenogeneic Patch
  • Allogeneic Patch

Application

  • Cardiovascular Repair
  • Cardiac Reconstruction
  • Vascular Reconstruction
  • Soft Tissue Repair
  • Abdominal Wall Reconstruction
  • Thoracic Wall Reconstruction
  • Dural Reconstruction
  • Hernia Repair
  • Others

End User

  • Hospitals
  • Ambulatory Surgical Centers
  • Specialty Clinics

Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

TABLE OF CONTENT

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Cardiovascular & Soft Tissue Repair Patch Market

4. Market Overview

    4.1. Introduction

        4.1.1. Product Definition

        4.1.2. Industry Evolution/Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Cardiovascular & Soft Tissue Repair Patch Market Analysis and Forecast, 2017–2027

5. Market Outlook

    5.1. Key Industry Events (product launch and approval, key merger & acquisition, etc.)

    5.2. Overview of Cardiovascular and Soft Tissue Repair Patch 

    5.3. Epidemiology of Cardiovascular Diseases, Soft Tissue Injury, Dural Injuries, Peripheral Injuries, by Region/Country 

6. Global Cardiovascular & Soft Tissue Repair Patch Market Analysis and Forecast, by Product

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by Product, 2017–2027

        6.3.1. Synthetic Patch

        6.3.2. Biologic Patch 

            6.3.2.1. Xenogeneic Patch 

            6.3.2.2. Allogeneic Patch

    6.4. Global Cardiovascular & Soft Tissue Repair Patch Market Attractiveness, by Product 

7. Global Cardiovascular & Soft Tissue Repair Patch Market Analysis and Forecast, by Application

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Global Cardiovascular & Soft Tissue Repair Patch Market Value Forecast, by Application, 2017–2027

        7.3.1. Cardiovascular Repair 

            7.3.1.1. Cardiac Reconstruction

            7.3.1.2. Vascular Reconstruction

        7.3.2. Soft Tissue Repair 

            7.3.2.1. Abdominal Wall Reconstruction

            7.3.2.2. Thoracic Wall Reconstruction

            7.3.2.3. Dural Reconstruction

            7.3.2.4. Hernia Repair 

            7.3.2.5. Others

    7.4. Global Cardiovascular & Soft Tissue Repair Patch Market Attractiveness, by Application

8. Global Cardiovascular & Soft Tissue Repair Patch Market Analysis and Forecast, by End-user 

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Global Cardiovascular & Soft Tissue Repair Patch Market Value Forecast, by End-user, 2017–2027

        8.3.1. Hospitals

        8.3.2. Ambulatory Surgical Centers

        8.3.3. Specialty Clinics

    8.4. Global Cardiovascular & Soft Tissue Repair Patch Market Attractiveness, by End-user 

9. Global Cardiovascular & Soft Tissue Repair Patch Market Analysis and Forecast, by Region

    9.1. Key Findings

    9.2. Market Value Forecast, by Region

        9.2.1. North America 

        9.2.2. Europe 

        9.2.3. Asia Pacific 

        9.2.4. Latin America 

        9.2.5. Middle East & Africa 

    9.3. Global Cardiovascular & Soft Tissue Repair Patch Market Attractiveness, by Country/Region

10. North America Cardiovascular & Soft Tissue Repair Patch Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. North America Cardiovascular & Soft Tissue Repair Patch Market Value Forecast, by Product, 2017–2027

        10.2.1. Synthetic Patch

        10.2.2. Biologic Patch 

            10.2.2.1. Xenogeneic Patch 

            10.2.2.2. Allogeneic Patch

    10.3. North America Cardiovascular & Soft Tissue Repair Patch Market Value Forecast, by Application, 2017–2027

        10.3.1. Cardiovascular Repair 

            10.3.1.1. Cardiac Reconstruction

            10.3.1.2. Vascular Reconstruction

        10.3.2. Soft Tissue Repair 

            10.3.2.1. Abdominal Wall Reconstruction

            10.3.2.2. Thoracic Wall Reconstruction

            10.3.2.3. Dural Reconstruction

            10.3.2.4. Hernia Repair 

            10.3.2.5. Others

    10.4. North America Cardiovascular & Soft Tissue Repair Patch Market Value Forecast, by End-user, 2017–2027

        10.4.1. Hospitals

        10.4.2. Ambulatory Surgical Centers

        10.4.3. Specialty Clinics

    10.5. North America Cardiovascular & Soft Tissue Repair Patch Market Value Forecast, by Country, 2017–2027

        10.5.1. U.S.

        10.5.2. Canada

    10.6. North America Cardiovascular & Soft Tissue Repair Patch Market Attractiveness Analysis 

        10.6.1. By Product 

        10.6.2. By Application

        10.6.3. By End-user 

        10.6.4. By Country

11. Europe Cardiovascular & Soft Tissue Repair Patch Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Europe Cardiovascular & Soft Tissue Repair Patch Market Value Forecast, by Product, 2017–2027

        11.2.1. Synthetic Patch

        11.2.2. Biologic Patch 

            11.2.2.1. Xenogeneic Patch 

            11.2.2.2. Allogeneic Patch

    11.3. Europe Cardiovascular & Soft Tissue Repair Patch Market Value Forecast, by Application, 2017–2027

        11.3.1. Cardiovascular Repair 

            11.3.1.1. Cardiac Reconstruction

            11.3.1.2. Vascular Reconstruction

        11.3.2. Soft Tissue Repair 

            11.3.2.1. Abdominal Wall Reconstruction

            11.3.2.2. Thoracic Wall Reconstruction

            11.3.2.3. Dural Reconstruction

            11.3.2.4. Hernia Repair 

            11.3.2.5. Others

    11.4. Europe Cardiovascular & Soft Tissue Repair Patch Market Value Forecast, by End-user, 2017–2027

        11.4.1. Hospitals

        11.4.2. Ambulatory Surgical Centers

        11.4.3. Specialty Clinics

    11.5. Europe Cardiovascular & Soft Tissue Repair Patch Market Value Forecast, by Country/Sub-region, 2017–2027

        11.5.1. Germany

        11.5.2. U.K.

        11.5.3. France

        11.5.4. Spain

        11.5.5. Italy

        11.5.6. Rest of Europe

    11.6. Europe Cardiovascular & Soft Tissue Repair Patch Market Attractiveness Analysis 

        11.6.1. By Product 

        11.6.2. By Application

        11.6.3. By End-user 

        11.6.4. By Country/Sub-region

12. Asia Pacific Cardiovascular & Soft Tissue Repair Patch Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Asia Pacific Cardiovascular & Soft Tissue Repair Patch Market Value Forecast, by Product, 2017–2027

        12.2.1. Synthetic Patch

        12.2.2. Biologic Patch 

            12.2.2.1. Xenogeneic Patch 

            12.2.2.2. Allogeneic Patch

    12.3. Asia Pacific Cardiovascular & Soft Tissue Repair Patch Market Value Forecast, by Application, 2017–2027

        12.3.1. Cardiovascular Repair 

            12.3.1.1. Cardiac Reconstruction

            12.3.1.2. Vascular Reconstruction

        12.3.2. Soft Tissue Repair 

            12.3.2.1. Abdominal Wall Reconstruction

            12.3.2.2. Thoracic Wall Reconstruction

            12.3.2.3. Dural Reconstruction

            12.3.2.4. Hernia Repair 

            12.3.2.5. Others

    12.4. Asia Pacific Cardiovascular & Soft Tissue Repair Patch Market Value Forecast, by End-user, 2017–2027

        12.4.1. Hospitals

        12.4.2. Ambulatory Surgical Centers

        12.4.3. Specialty Clinics

    12.5. Asia Pacific Cardiovascular & Soft Tissue Repair Patch Market Value Forecast, by Country/Sub-region, 2017–2027

        12.5.1. China

        12.5.2. Japan

        12.5.3. India

        12.5.4. Australia & New Zealand

        12.5.5. Rest of Asia Pacific

    12.6. Asia Pacific Cardiovascular & Soft Tissue Repair Patch Market Attractiveness Analysis 

        12.6.1. By Product 

        12.6.2. By Application

        12.6.3. By End-user 

        12.6.4. By Country/Sub-region

13. Latin America Cardiovascular & Soft Tissue Repair Patch Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Latin America Cardiovascular & Soft Tissue Repair Patch Market Value Forecast, by Product, 2017–2027

        13.2.1. Synthetic Patch

        13.2.2. Biologic Patch 

            13.2.2.1. Xenogeneic Patch 

            13.2.2.2. Allogeneic Patch

    13.3. Latin America Cardiovascular & Soft Tissue Repair Patch Market Value Forecast, by Application, 2017–2027

        13.3.1. Cardiovascular Repair 

            13.3.1.1. Cardiac Reconstruction

            13.3.1.2. Vascular Reconstruction

        13.3.2. Soft Tissue Repair 

            13.3.2.1. Abdominal Wall Reconstruction

            13.3.2.2. Thoracic Wall Reconstruction

            13.3.2.3. Dural Reconstruction

            13.3.2.4. Hernia Repair 

            13.3.2.5. Others

    13.4. Latin America Cardiovascular & Soft Tissue Repair Patch Market Value Forecast, by End-user, 2017–2027

        13.4.1. Hospitals

        13.4.2. Ambulatory Surgical Centers

        13.4.3. Specialty Clinics

    13.5. Latin America Cardiovascular & Soft Tissue Repair Patch Market Value Forecast, by Country/Sub-region, 2017–2027

        13.5.1. Brazil

        13.5.2. Mexico

        13.5.3. Rest of Latin America

    13.6. Latin America Cardiovascular & Soft Tissue Repair Patch Market Attractiveness Analysis 

        13.6.1. By Product 

        13.6.2. By Application

        13.6.3. By End-user 

        13.6.4. By Country/Sub-region

14. Middle East & Africa Cardiovascular & Soft Tissue Repair Patch Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Middle East & Africa Cardiovascular & Soft Tissue Repair Patch Market Value Forecast, by Product, 2017–2027

        14.2.1. Synthetic Patch

        14.2.2. Biologic Patch 

            14.2.2.1. Xenogeneic Patch 

            14.2.2.2. Allogeneic Patch

    14.3. Middle East & Africa Cardiovascular & Soft Tissue Repair Patch Market Value Forecast, by Application, 2017–2027

        14.3.1. Cardiovascular Repair 

            14.3.1.1. Cardiac Reconstruction

            14.3.1.2. Vascular Reconstruction

        14.3.2. Soft Tissue Repair 

            14.3.2.1. Abdominal Wall Reconstruction

            14.3.2.2. Thoracic Wall Reconstruction

            14.3.2.3. Dural Reconstruction

            14.3.2.4. Hernia Repair 

            14.3.2.5. Others

    14.4. Middle East & Africa Cardiovascular & Soft Tissue Repair Patch Market Value Forecast, by End-user, 2017–2027

        14.4.1. Hospitals

        14.4.2. Ambulatory Surgical Centers

        14.4.3. Specialty Clinics

    14.5. Middle East & Africa Cardiovascular & Soft Tissue Repair Patch Market Value Forecast, by Country/Sub-region, 2017–2027

        14.5.1. GCC Countries

        14.5.2. South Africa

        14.5.3. Rest of Middle East & Africa

    14.6. Middle East & Africa Cardiovascular & Soft Tissue Repair Patch Market Attractiveness Analysis 

        14.6.1. By Product 

        14.6.2. By Application

        14.6.3. By End-user 

        14.6.4. By Country/Sub-region

15. Competition Landscape

    15.1. Market Player - Competition Matrix (By Tier and Size of companies)

    15.2. Market Share Analysis/Ranking, by Company, 2018

    15.3. Company Profiles

        15.3.1. W. L. Gore & Associates, Inc. 

            15.3.1.1. Company Overview

            15.3.1.2. Growth Strategies

            15.3.1.3. SWOT Analysis

        15.3.2. BD

            15.3.2.1. Company Overview

            15.3.2.2. Company Financials

            15.3.2.3. Growth Strategies

            15.3.2.4. SWOT Analysis

        15.3.3. Edwards Lifesciences Corporation 

            15.3.3.1. Company Overview

            15.3.3.2. Company Financials

            15.3.3.3. Growth Strategies

            15.3.3.4. SWOT Analysis

        15.3.4. CryoLife, Inc.

            15.3.4.1. Company Overview

            15.3.4.2. Company Financials

            15.3.4.3. Growth Strategies

            15.3.4.4. SWOT Analysis

        15.3.5. Baxter International, Inc.

            15.3.5.1. Company Overview

            15.3.5.2. Company Financials

            15.3.5.3. Growth Strategies

            15.3.5.4. SWOT Analysis

        15.3.6. Johnson & Johnson (Medical Devices Business Services, Inc.) 

            15.3.6.1. Company Overview

            15.3.6.2. Company Financials

            15.3.6.3. Growth Strategies

            15.3.6.4. SWOT Analysis

        15.3.7. Aesculap, Inc. (a B. Braun company)

            15.3.7.1. Company Overview

            15.3.7.2. Company Financials

            15.3.7.3. Growth Strategies

            15.3.7.4. SWOT Analysis

        15.3.8. Nurami Medical Nanofiber Technology 

            15.3.8.1. Company Overview

            15.3.8.2. Growth Strategies

            15.3.8.3. SWOT Analysis

        15.3.9. Medtronic

            15.3.9.1. Company Overview

            15.3.9.2. Company Financials

            15.3.9.3. Growth Strategies

            15.3.9.4. SWOT Analysis

        15.3.10. FOC Medical S.A. 

            15.3.10.1. Company Overview

            15.3.10.2. Growth Strategies

            15.3.10.3. SWOT Analysis

        15.3.11. Medprin Regenerative Medical Technologies Co., Ltd.

            15.3.11.1. Company Overview

            15.3.11.2. Growth Strategies

            15.3.11.3. SWOT Analysis

        15.3.12. CorMatrix, Inc.

            15.3.12.1. Company Overview

            15.3.12.2. Growth Strategies

            15.3.12.3. SWOT Analysis

        15.3.13. Terumo Corporation 

            15.3.13.1. Company Overview

            15.3.13.2. Company Financials

            15.3.13.3. Growth Strategies

            15.3.13.4. SWOT Analysis

        15.3.14. Lamed GmbH 

            15.3.14.1. Company Overview

            15.3.14.2. Growth Strategies

            15.3.14.3. SWOT Analysis

        15.3.15. South America Implants S.A.

            15.3.15.1. Company Overview

            15.3.15.2. Growth Strategies

            15.3.15.3. SWOT Analysis

Choose License Type

Checkout Inquiry Sample